Počet záznamů: 1
Arylazopyrazole AAP1742 Inhibits CDKs and Induces Apoptosis in Multiple Myeloma Cells via Mcl-1 Downregulation
- 1.0433741 - ÚEB 2015 RIV GB eng J - Článek v odborném periodiku
Jorda, Radek - Navrátilová, Jana - Hušková, Zlata - Schütznerová, E. - Cankař, P. - Strnad, Miroslav - Kryštof, Vladimír
Arylazopyrazole AAP1742 Inhibits CDKs and Induces Apoptosis in Multiple Myeloma Cells via Mcl-1 Downregulation.
Chemical Biology & Drug Design. Roč. 84, č. 4 (2014), s. 402-408. ISSN 1747-0277. E-ISSN 1747-0285
Grant CEP: GA ČR GAP305/12/0783; GA ČR GA14-19590S; GA MŠMT(CZ) LO1204
Institucionální podpora: RVO:61389030
Klíčová slova: CAN508 * cyclin-dependent kinase * inhibitor
Kód oboru RIV: EB - Genetika a molekulární biologie
Impakt faktor: 2.485, rok: 2014
http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=Alerting&SrcApp=Alerting&DestApp=MEDLINE&DestLinkType=FullRecord&UT=24803299
Inhibitors of cyclin-dependent kinases 9 have been developed as potential anticancer drugs for the treatment of multiple myeloma. We have previously prepared a library of arylazo-3,5-diaminopyrazole inhibitors of CDKs. Here, we describe a novel member, AAP1742 (CDK9 inhibition with IC50 =0.28mum), that reduces the viability of multiple myeloma cell lines in low micromolar concentrations. Consistent with inhibition of CDK9, AAP1742 decreases the phosphorylation of RNA polymerase II and inhibits mRNA synthesis of anti-apoptotic proteins Mcl-1, Bcl-2, and XIAP, followed by apoptosis in the RPMI-8226 cell line in a dose- and a time-dependent manner. These results are consistent with the biochemical profile of AAP1742 and further suggest cellular inhibition of CDK9 as a possible target for anticancer drugs.
Trvalý link: http://hdl.handle.net/11104/0237916
Název souboru Staženo Velikost Komentář Verze Přístup 2014_Jorda_CHEMICAL BIOLOGY & DRUG DESIGN_402.pdf 1 801.1 KB Jiná povolen
Počet záznamů: 1